Eighty-five percent of clinical trials fail to recruit enough patients, and 80% face delays from participant dropouts and related issues. These aren’t minor setbacks. Every month a trial falls behind schedule costs sponsors significant money and delays treatments from reaching the people who need them. The good news: a growing set of proven strategies can dramatically shorten enrollment timelines and broaden the pool of willing participants.
Why Recruitment Fails So Often
Most recruitment problems trace back to a handful of root causes. Overly narrow eligibility criteria screen out patients who could safely participate. Trial sites cluster in academic medical centers that many patients can’t easily reach. Protocols demand too many in-person visits, blood draws, and assessments, pushing the time commitment beyond what working adults can absorb. And perhaps most fundamentally, most people who qualify for a trial never hear about it in the first place.
On the physician side, the referral pipeline is leaky. Research on oncologists found that the single biggest factor separating doctors who refer patients from those who don’t is the perceived burden of the process. Non-referring physicians cited excessive paperwork, overly detailed protocols, and a lack of staff support as their top reasons for not sending patients to active trials. If the referring physician finds the process exhausting, eligible patients never enter the funnel at all.
Use Electronic Health Records to Find Eligible Patients
Manually screening medical records for trial-eligible patients is one of the most time-consuming steps in recruitment. Automated matching software that scans electronic health records against eligibility criteria can compress this work dramatically. In a pilot study across multiple trials, automated screening reduced the staff time needed to identify each eligible patient by up to 19-fold compared to manual chart review. Across the study period, research teams saved between 165 and 1,329 hours of screening labor.
The tradeoff is accuracy. Automated systems flag patients who look eligible on paper but turn out not to be. In the same pilot, “true eligible” yields ranged from about 17% to 74% depending on the complexity of the trial’s criteria. That means your team still needs to verify each flagged patient. But even with those false positives, the net time savings were substantial for nearly every trial tested. The key is building eligibility logic that’s specific enough to keep false-positive rates manageable while still casting a wide net.
Decentralize the Trial Experience
Requiring patients to visit a hospital or research center repeatedly is one of the fastest ways to lose them. Decentralized trial designs, where participants complete some or all activities from home using wearable sensors, smartphone apps, or telehealth visits, have shown they can accelerate enrollment to a degree that traditional site-based models rarely match.
The numbers from fully remote studies are striking. The DETECT trial, which used a bring-your-own-device approach where participants used their existing smartphones and wearables, enrolled 41,000 participants in just four weeks. A remote cognitive health study called Intuition recruited thousands of participants within its first three months. These are outliers in scale, but they illustrate the core principle: when you remove the requirement to physically show up, many more people say yes.
You don’t have to go fully remote to benefit. Hybrid models that combine occasional site visits with home-based data collection and virtual check-ins reduce patient travel burden while still allowing the clinical assessments that some protocols require. Even offering a single home-visit option for blood draws or physical exams can meaningfully improve retention rates.
Reduce What You’re Asking Patients to Do
Patient burden is measurable, and it directly affects who enrolls and who drops out. A survey of 258 trial participants found that assessments lasting longer than 30 minutes and those required multiple times per month were associated with significantly higher perceived burden. The perception of burden also varied by age and ethnicity, meaning a protocol that feels manageable to one demographic may feel overwhelming to another.
Practical steps to lighten the load include consolidating study visits so patients make fewer trips, shortening questionnaires to capture only what’s essential, and spacing out assessments when clinical endpoints allow it. Every additional form, blood draw, or clinic visit is a point where a participant might decide the trial isn’t worth the disruption to their life. Protocol designers who audit their requirements with the patient’s weekly schedule in mind, not just the data team’s wish list, tend to build studies that recruit and retain more effectively.
Travel is another underappreciated barrier. Research on cancer trial participants found that lower-income patients faced median travel costs roughly four to five times higher than wealthier participants, largely because they lived farther from academic medical centers. Reimbursing travel expenses, offering rideshare vouchers, or adding community-based satellite sites can remove a barrier that disproportionately excludes the patients trials most need.
Make Physician Referrals Easier
Since paperwork burden is the top reason physicians don’t refer patients, the fix is structural: simplify the referral itself. A one-page summary of eligibility criteria, a single-click referral form in the EHR, and a dedicated coordinator who handles the logistics after the referral all reduce friction. If you’re running a multi-site trial, providing each site with a staff member whose sole job is managing incoming referrals can turn non-referring physicians into active recruitment partners.
Awareness matters too. Many community physicians simply don’t know which trials are enrolling at any given time. Regular, brief updates sent to relevant specialists, formatted as a patient profile rather than a protocol synopsis (“looking for adults 40-65 with moderate asthma who haven’t responded to standard inhalers”), make it easy for a busy clinician to think of a specific patient and act on it.
Engage Communities, Not Just Institutions
Clinical trials have long struggled with diversity. Federal legislation now requires sponsors to submit diversity action plans for certain trials, but meeting those requirements takes more than broadening the age range on a flyer. Building trust with historically underrepresented communities requires sustained, relationship-based engagement.
One model gaining traction is integrating community health workers into research teams. These are people already embedded in their neighborhoods, trusted by residents, and familiar with local concerns about medical research. In focus groups with community health workers and community members, there was consensus that these workers, because of their existing relationships and cultural knowledge, are uniquely positioned to recruit Black participants and other underrepresented groups into clinical research. As one community health worker described it: “We’re the link in the community. People come to us and say, ‘What do you think about this?'”
This approach works because it addresses the trust deficit that no amount of advertising can overcome on its own. Community health workers can explain a trial in culturally relevant terms, answer questions honestly, and follow up in ways that feel personal rather than transactional. Including them on the research team from the design phase, not just the recruitment phase, also helps ensure the study itself is structured in ways that are accessible to the communities you want to reach.
Use Digital Advertising Strategically
Social media advertising on platforms like Facebook and Instagram can reach large numbers of potential participants quickly and with precise demographic targeting. The appeal is obvious: you can put a trial opportunity in front of people who match your eligibility criteria by age, location, health interests, and more, often for a fraction of what traditional media costs.
The challenge is converting clicks into enrolled participants. Someone who taps a Facebook ad is at the very top of the funnel. Between that click and a signed consent form sit a pre-screening questionnaire, a phone call, an eligibility review, and often an in-person visit. Each step loses people. To maximize conversion, keep the initial response step as short as possible (a brief online form, not a 20-minute survey), respond to inquiries within 24 hours, and assign a real person to guide interested patients through the next steps by phone or text.
Digital ads work best as one channel in a broader strategy. Pair them with community outreach, physician referrals, and EHR-based identification so you’re reaching patients through multiple touchpoints. People who see a trial mentioned by their doctor and then encounter it again on social media are far more likely to take action than those who see only an ad.
Pay Participants Fairly
Compensating trial participants is standard practice and broadly accepted by regulators. The FDA considers payment a recruitment incentive, not a study benefit, and requires that institutional review boards evaluate both the amount and the payment schedule to ensure neither is coercive. Reimbursing travel, parking, and lodging expenses is considered separately and doesn’t raise concerns about undue influence.
The practical guidance is straightforward. Pay people for their time, inconvenience, and discomfort. Don’t make the entire payment contingent on completing the full study, as that pressures people to stay when they’d otherwise withdraw. A small completion bonus is acceptable, but it shouldn’t be so large that it overrides a participant’s judgment about whether to continue. Spread payments across visits so people aren’t financially penalized for dropping out partway through.
Getting compensation right matters for both recruitment and retention. Underpaying signals that you don’t value participants’ time. Overpaying, or structuring payments to penalize withdrawal, undermines informed consent. The sweet spot is compensation that acknowledges the real costs of participation, including lost wages, childcare, and travel, without turning the payment itself into the reason someone enrolls in a study they’re uncomfortable with.